Potential association between membranous nephropathy and sargramostim therapy for pulmonary alveolar proteinosis

Sewaralthahab, Kamal; Rennke, Helmut G.; Sewaralthahab, Sarah; Madias, Nicolaos E.; Jaber, Bertrand L.

doi:10.5414/cncs108420

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In such cases, notably in a NELL1 positive patient, significant improvement was achieved by discontinuing such medication [89]. Another case report described the onset of MN in a patient due to sargramostim, a recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF), who recovered completely after discontinuation [90]. Secondary MN may also occur in association with autoimmune liver diseases such as primary sclerosing cholangitis, primary biliary cirrhosis or autoimmune hepatitis.…”

Section: Treatment Of Secondary Membranous Nephropathymentioning

confidence: 99%

How to Choose the Right Treatment for Membranous Nephropathy

Peritore,

Labbozzetta,

Maressa

et al. 2023

Medicina

View full text Add to dashboard Cite

Membranous nephropathy is an autoimmune disease affecting the glomeruli and is one of the most common causes of nephrotic syndrome. In the absence of any therapy, 35% of patients develop end-stage renal disease. The discovery of autoantibodies such as phospholipase A2 receptor 1, antithrombospondin and neural epidermal growth factor-like 1 protein has greatly helped us to understand the pathogenesis and enable the diagnosis of this disease and to guide its treatment. Depending on the complications of nephrotic syndrome, patients with this disease receive supportive treatment with diuretics, ACE inhibitors or angiotensin-receptor blockers, lipid-lowering agents and anticoagulants. After assessing the risk of progression of end-stage renal disease, patients receive immunosuppressive therapy with various drugs such as cyclophosphamide, steroids, calcineurin inhibitors or rituximab. Since immunosuppressive drugs can cause life-threatening side effects and up to 30% of patients do not respond to therapy, new therapeutic approaches with drugs such as adrenocorticotropic hormone, belimumab, anti-plasma cell antibodies or complement-guided drugs are currently being tested. However, special attention needs to be paid to the choice of therapy in secondary forms or in specific clinical contexts such as membranous disease in children, pregnant women and patients undergoing kidney transplantation.

show abstract

Section: Treatment Of Secondary Membranous Nephropathymentioning

confidence: 99%